News Image

NASDAQ:NBIX qualifies as a high growth stock and is consolidating.

By Mill Chart

Last update: Sep 26, 2023

Exploring Growth Potential: NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) and Its Base Formation. Growth investors seek promising revenue and EPS growth, and NEUROCRINE BIOSCIENCES INC has come under our scrutiny for potential growth investing. While it's crucial to do your own research, we've detected NEUROCRINE BIOSCIENCES INC on our screen for growth with base formation, suggesting it merits a closer look.

A Closer Look at Growth for NASDAQ:NBIX

To evaluate a stock's growth potential, ChartMill utilizes a Growth Rating on a scale of 0 to 10. This comprehensive assessment considers various growth aspects, including historical and estimated EPS and revenue growth. NASDAQ:NBIX has achieved a 9 out of 10:

  • NBIX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 232.69%, which is quite impressive.
  • NBIX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 66.75% yearly.
  • The Revenue has grown by 29.01% in the past year. This is a very strong growth!
  • Measured over the past years, NBIX shows a very strong growth in Revenue. The Revenue has been growing by 55.91% on average per year.
  • NBIX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 48.84% yearly.
  • The Revenue is expected to grow by 15.72% on average over the next years. This is quite good.

Understanding NASDAQ:NBIX's Health

Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:NBIX has achieved a 7 out of 10:

  • NBIX has an Altman-Z score of 9.99. This indicates that NBIX is financially healthy and has little risk of bankruptcy at the moment.
  • NBIX's Altman-Z score of 9.99 is amongst the best of the industry. NBIX outperforms 88.58% of its industry peers.
  • NBIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
  • NBIX has a Current Ratio of 2.57. This indicates that NBIX is financially healthy and has no problem in meeting its short term obligations.
  • NBIX has a Quick Ratio of 2.51. This indicates that NBIX is financially healthy and has no problem in meeting its short term obligations.

Exploring NASDAQ:NBIX's Profitability

Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NASDAQ:NBIX has achieved a 8:

  • Looking at the Return On Assets, with a value of 6.75%, NBIX belongs to the top of the industry, outperforming 96.19% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 9.52%, NBIX belongs to the top of the industry, outperforming 95.86% of the companies in the same industry.
  • With an excellent Return On Invested Capital value of 11.65%, NBIX belongs to the best of the industry, outperforming 97.02% of the companies in the same industry.
  • Looking at the Profit Margin, with a value of 10.54%, NBIX belongs to the top of the industry, outperforming 95.53% of the companies in the same industry.
  • NBIX's Profit Margin has improved in the last couple of years.
  • NBIX has a Operating Margin of 17.60%. This is amongst the best in the industry. NBIX outperforms 96.85% of its industry peers.
  • With an excellent Gross Margin value of 97.98%, NBIX belongs to the best of the industry, outperforming 98.18% of the companies in the same industry.

How does the Setup look for NASDAQ:NBIX

Next to the Technical Rating, the Setup Rating of a stock determines to which extend the stock is consolidating. This score also ranges from 0 to 10 and is updated daily. The setup score evaluates various short term technical indicators. For NASDAQ:NBIX this score is currently 8:

NBIX has an excellent technical rating and also presents a decent setup pattern. Prices have been consolidating lately and the volatility has been reduced. There is very little resistance above the current price. There is a support zone below the current price at 113.67, a Stop Loss order could be placed below this zone.

Every day, new Strong Growth stocks can be found on ChartMill in our Strong Growth screener.

For an up to date full fundamental analysis you can check the fundamental report of NBIX

Our latest full technical report of NBIX contains the most current technical analsysis.

Keep in mind

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.

Back

NEUROCRINE BIOSCIENCES INC

NASDAQ:NBIX (4/26/2024, 7:05:57 PM)

After market: 135.99 0 (0%)

135.99

-1.77 (-1.28%)

NBIX News

News Image2 days ago - Investor's Business DailyStock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review

Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser.

News Image4 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of WHAT THE C@H?!, an educational initiative that aims to close the gap...

News Image4 days ago - InvestorPlace3 Red-Hot Biotech Rockets Blasting Off in 2024

The economy is looking very strong and the biotech industry even more so, thus consider these top three stocks for strong profits.

News Image5 days ago - Investor's Business DailyNo. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win

The company is establishing its line-up of drugs behind bread-and-butter med Ingrezza.

News Image12 days ago - Sentia Medical Sciences, Inc.Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
News Image17 days ago - ChartmillWhy NASDAQ:NBIX Is a Standout High-Growth Stock in a Consolidation Phase.

Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Promising High-Growth Stock in the Midst of Consolidation.

News Image18 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2024 financial results conference call and...

News Image18 days ago - ChartmillFor those who appreciate growth without the sticker shock, NASDAQ:NBIX is worth considering.

Looking for growth without the hefty price tag? Consider NASDAQ:NBIX.

News Image25 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the first patient has been randomized for its Phase 2 clinical study to...

News Imagea month ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 clinical study to evaluate the safety, tolerability,...

News Imagea month ago - Investor's Business DailyS&P 500 Giants Lead Five Stocks Near Buy Points With Fed's Powell A Tailwind

DexCom, Blackstone and Royal Caribbean head this list of five stocks.

News Imagea month ago - Investor's Business DailyMadrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark

On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago.

NBIX Links
Follow us for more